If all goes according to its revised plan, Moderna (NASDAQ: MRNA) will have far more doses of its coronavirus vaccine on the market than formerly anticipated. The company announced Monday that it is lifting its base-case estimate for global production of mRNA-1273 in 2021 to 600 million doses from the previous forecast of 500 million.
Ideally, it will produce as many as 1 billion for the year. It is currently adding staff in order to reach such capacity.
Among other factors, Moderna is basing its new estimate on the initial rollouts of the coronavirus vaccine throughout North America.